HIVE vs HUT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 01, 2026

HIVE

56.4
AI Score
VS
HIVE Wins

HUT

54.8
AI Score

Investment Advisor Scores

HIVE

56score
Recommendation
HOLD

HUT

55score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HIVE HUT Winner
Revenue 71.02M 225.97M HIVE
Net Income -219.85M -72.11M HIVE
Net Margin -309.6% -31.9% HIVE
ROE -15.9% -12.9% HIVE
ROA -8.4% -11.6% HUT
Total Assets 2.61B 624.00M HUT
Cash 160.02M 14.07M HUT
Current Ratio 0.86 1.74 HIVE

Relative Price Performance (Last 90 Days)

HIVE 1M: -18.2% · 3M: +17.4% HUT 1M: +1.7% · 3M: +42.0%

Current Technical Phase

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 42

RSI (14): 42.0 · Price: $2.83

HUT

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 51.3 · Price: $107.63

Fundamentals Snapshot

Metric HIVE HUT
Market Cap
Forward P/E -5.5 -42.9
Trailing P/E
Revenue (TTM)
Revenue Growth 1.3% 2.3%
Gross Margin 0.4% 0.6%
Operating Margin -0.8% -5.2%
EPS -0.78 -3.46
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.